Skip to main content

Table 2 Outcomes of the 14 including articles

From: Effects of bisphosphonates in preventing periprosthetic bone loss following total hip arthroplasty: a systematic review and meta-analysis

Study (author/year) BMD (mean ± SD) (g/cm2) BAP (mean ± SD) (U/L) (BPs vs. control) NTX-I (mean ± SD) (nmol/mmol Cr) (BPs vs. control)
1 year (BPs vs. control) 2–4 years (BPs vs. control) ≥ 5 years (BPs vs. control)
Tapaninen TS/2010 [18] − 0.04 ± 0.09 vs. − 0.12 ± 0.10 − 0.05 ± 0.12 vs. − 0.18 ± 0.21 − 0.06 ± 0.12 vs. − 0.16 ± 0.24 NA NA
Trevisan C/2010 [19] − 0.04 ± 0.07 vs. − 0.07 ± 0.08 NA NA NA NA
Arabmotlagh M/2009 [20] − 0.02 ± 0.16 vs. − 0.04 ± 0.09 NA − 0.02 ± 0.17 vs. − 0.06 ± 0.20 NA NA
Yamasaki S/2007 [21] NA NA NA 21.5 ± 7.7 vs. 31.2 ± 9.6 39.2 ± 15.9 vs.70.3 ± 27.7
Fokter SK/2006 [22] − 0.06 ± 0.07 vs. − 0.06 ± 0.23 NA NA NA NA
Arabmotlagh M/2006 [23] 0 ± 0.16 vs. − 0.07 ± 0.22 NA NA 17.9 ± 6 vs. 27.1 ± 8.9 NA
Yamaguchi K/2004 [24] − 0.06 ± 0.12 vs. − 0.12 ± 0.14 − 0.09 ± 0.13 vs. − 0.13 ± 0.13 NA 25.2 ± 6.6 vs. 29.6 ± 8.7 52.5 ± 29.2 vs. 71.3 ± 17.8
Iwamoto N/2011 [25] 0 ± 0.12 vs. − 0.08 ± 0.14 NA NA NA NA
Kinov P/2006 [26] NA NA NA 19.93 ± 6.6 vs. 26.9 ± 5.9 NA
Shetty N/2006 [27] − 0.01 ± 0.07 vs. − 0.02 ± 0.14 − 0.02 ± 0.05 vs. − 0.01 ± 0.16 − 0.02 ± 0.01 vs. − 0.03 ± 0.2 NA NA
Scott DF/2013 [28] 0.80 ± 10.4 vs. − 6.03 ± 13.2 − 0.16 ± 14.0 vs. − 7.13 ± 12.7 NA NA NA
Yukizawa Y/2017 [29] − 0.04 ± 0.02 vs. − 0.13 ± 0.02 NA − 0.12 ± 0.03 vs. − 0.21 ± 0.02 NA NA
Muren O/2015 [30] NA − 0.19 ± 0.02 vs. − 0.22 ± 0.03 NA NA NA
Nehme A/2003 [31] − 0.24 ± 0.07 vs. − 0.32 ± 0.07 − 0.09 ± 0.06 vs. − 0.16 ± 0.06 NA NA NA
  1. BPs bisphosphonates, BMD bone mineral density, BAP serum bone alkaline phosphates, NTX-I urinary N-telopeptide of type I collagen, NA not applicable